The chief executive of Novartis sent employees an email Thursday seeking to contain intensifying political and business fallout over the revelation that the drug maker paid $1.2 million to President Trump’s personal lawyer to gain access to the White House.

“Yesterday was not a good day for Novartis,” wrote Vasant Narasimhan, a physician and former McKinsey consultant, who joined the drug maker more than a decade ago and oversaw global drug development before being promoted to chief executive this past February.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • While not the best thing to happen to NVS, we should wait to see how things shake out with the new CEO on this. If involved then he should be accountable but this may all have been done without his knowledge but only time will tell. This is not the same organization I worked at years back, and something like this is not shocking, but it is much to soon to lump all executives into this right now

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy